Estimands and estimation in trials with time trends

📅 2026-09-30
📈 Citations: 0
✨ Influential: 0
📄 PDF
🤖 AI Summary
This study addresses the challenges of estimating causal effects under cross-temporal trends in platform trials, where ambiguous target definitions and biases arising from pooling multi-period data remain unresolved. To tackle these issues, the authors systematically delineate conditional and marginal estimands and comprehensively evaluate the bias-variance trade-offs of model-based approaches, G-computation, and augmented inverse probability weighting (AIPW) estimators under complex temporal dynamics. The work reveals how estimator performance evolves with varying target populations and data selection strategies, thereby clarifying the applicability boundaries of each methodological approach. Ultimately, these findings provide a robust statistical foundation for regulatory decision-making in adaptive platform trial settings.
📝 Abstract
In platform trials, model-based approaches typically estimate treatment effects conditional on calendar time. However, scientific and regulatory interest often lies in treatment effects defined for a target population spanning multiple enrollment periods, requiring explicit consideration of how effects should be averaged across time. This raises two fundamental challenges. The first is the definition of the appropriate target estimand when combining data across multiple periods. The second is the selection of the estimator to be used. In this work, we examine conditional and marginal estimands in platform trials with time trends, and describe target populations of interest. To address the second challenge, we evaluate model-based, G-computation and augmented inverse probability weighting estimators, comparing their bias and variance. We discuss how the choice of estimand, target population and trial data used for estimation affects estimator performance.
Problem

Research questions and friction points this paper is trying to address.

platform trials
time trends
estimands
treatment effects
estimation
Innovation

Methods, ideas, or system contributions that make the work stand out.

Platform trials
Time trends
Estimands
G-computation
Augmented inverse probability weighting
🔎 Similar Papers
No similar papers found.
M
Marta Bofill Roig
Department of Statistics and Operations Research and Institute for Research and Innovation in Health (IRIS), Universitat Politècnica de Catalunya - BarcelonaTech, Barcelona, Spain
E
Ekkehard Glimm
Advanced Methodology and Data Science, Novartis Pharma AG, Basel, Switzerland
Kelly Van Lancker
Kelly Van Lancker
Assistant Professor and Postdoctoral researcher in Biostatistics, Ghent University
Biostatisticsclinical trials
M
Martin Posch
Center for Medical Data Science, Medical University of Vienna, Vienna, Austria